MARKET

TBPH

TBPH

Theravance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.23
-0.98
-5.69%
Closed 16:00 11/23 EST
OPEN
17.35
PREV CLOSE
17.21
HIGH
17.35
LOW
16.17
VOLUME
366.20K
TURNOVER
--
52 WEEK HIGH
31.54
52 WEEK LOW
14.48
MARKET CAP
1.04B
P/E (TTM)
-3.4314
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Theravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx Conference
Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast a presentation as follows:
PR Newswire · 11/17 11:00
Theravance (TBPH) Drops on Q3 Earnings Miss, Revenues In Line
Theravance (TBPH) falls more than 13% as it reports wider-than-expected loss for the third quarter of 2020. Revenues meet estimates.
Zacks · 11/09 17:17
Analysts Have Lowered Expectations For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Its Latest Results
Last week, you might have seen that Theravance Biopharma, Inc. (NASDAQ:TBPH) released its quarterly result to the...
Simply Wall St. · 11/09 15:20
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates
Zacks · 11/06 00:05
Theravance Biopharma Sees FY 2020 Operating Loss Between $(225M) And $(235M)
DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial results for the third
Benzinga · 11/05 21:57
Theravance Biopharma Q3 EPS $(1.16) Misses $(0.97) Estimate, Sales $18.30M Miss $18.58M Estimate
Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.97) by 19.59 percent. This is a 10.48 percent decrease over losses of $(1.05) per share
Benzinga · 11/05 21:56
Theravance Biopharma EPS misses by $0.15, misses on revenue
Theravance Biopharma (TBPH): Q3 GAAP EPS of -$1.16 misses by $0.15.Revenue of $18.26M (+46.9% Y/Y) misses by $0.32M.Press Release
Seekingalpha · 11/05 21:39
Theravance Biopharma, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Theravance Biopharma, Inc.
ACCESSWIRE · 11/05 20:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TBPH. Analyze the recent business situations of Theravance through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TBPH stock price target is 31.67 with a high estimate of 42.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 181
Institutional Holdings: 71.80M
% Owned: 112.22%
Shares Outstanding: 63.98M
TypeInstitutionsShares
Increased
34
5.24M
New
31
-64.58K
Decreased
50
5.41M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.87%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Chief Executive Officer/Director
Rick Winningham
Chief Financial Officer/Senior Vice President
Andrew Hindman
Corporate Executive
Ann Brady
Executive Vice President/General Counsel/Secretary
Bradford Shafer
Senior Vice President
Brett Haumann
Senior Vice President
.. ..
Senior Vice President
Frank Pasqualone
Senior Vice President
Kenneth Pitzer
Senior Vice President
Vijay Sabesan
Senior Vice President
Philip Worboys
Lead Director/Independent Director
William Young
Director
Robert Gunderson
Independent Director
Laurie Alsup
Independent Director
Eran Broshy
Independent Director
Burton Malkiel
Independent Director
Dean Mitchell
Independent Director
Susan Molineaux
Independent Director
Donal O'Connor
Independent Director
Deepika Pakianathan
Independent Director
George Whitesides
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Theravance Biopharma Inc stock information, including NASDAQ:TBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TBPH stock methods without spending real money on the virtual paper trading platform.